Evidence map›Paper›PMID 29892560›Full record

ArticleJournal of clinical & translational endocrinology2018

Vitamin D3 supplementation in obese, African-American, vitamin D deficient adolescents.

Sheela N Magge, Divya Prasad, Babette S Zemel, Andrea Kelly

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Vitamin D and Cardiovascular Risk: which Implications in Children?International journal of molecular sciences · 2020
    Review
  6. Article
  7. Vitamin D Supplementation In Obese Africian American Children.Journal of clinical & translational endocrinology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sheela N MaggeDivision of Pediatric Endocrinology, Johns Hopkins University School of Medicine, United States.
Divya PrasadDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, United States.
Babette S ZemelDivision of GI, Hepatology and Nutrition, The Children's Hospital of Philadelphia, United States.
Andrea KellyDivision of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, United States.
Children's Hospital of Philadelphia · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesObese, African-American (AA) adolescents are at increased risk for vitamin D deficiency. The primary objective of this pilot study was to examine the effect of vitamin D supplementation upon 25-hydroxy vitamin D (25OHD) levels in obese, AA adolescents.

methodsA randomized, double-blinded, controlled pilot study included 26 obese (BMI ≥ 95%ile), vitamin D deficient (25OHD < 20 ng/mL), pubertal AA adolescents (ages 12-17). Subjects received cholecalciferol 1000 IU or 5000 IU daily for 3 months. Serum 25OHD, vitamin D binding protein, parathyroid hormone, and cardiometabolic risk markers were obtained at baseline and post-treatment.

resultsOf 39 subjects enrolled, 26 (67%) were vitamin D deficient (mean 25OHD 12.0 ± 3.8 ng/mL) at baseline and were randomized, with 22 completing the study. Sex, age, season, pubertal stage, BMI, insulin resistance (HOMA-IR) and 25OHD were similar at baseline between the 1000 IU and 5000 IU groups. Post-treatment, 25OHD increased less in the 1000 IU group (5.6 ng/mL, p = 0.03) vs. the 5000 IU group (15.6 ng/mL, p = 0.002). 83% of the 5000 IU group and 30% of the 1000 IU group reached post-treatment 25OHD ≥ 20 ng/mL (p = 0.01); 50% of the 5000 IU group, but no subject from the 1000 IU group, achieved 25OHD ≥ 30 ng/mL (p = 0.009). We detected no group differences in mineral metabolites or cardiometabolic risk markers following supplementation.

conclusionsCholecalciferol dosing in excess of the current Institute of Medicine dietary reference intakes was required to achieve 25OHD levels ≥20 ng/mL in obese, AA adolescents. Supplementation of 5000 IU may be required to achieve the desired goal.

Indexed as

25OHD, 25-hydroxy vitamin DAA, African-AmericanAAP, American Academy of PediatricsBG, blood glucoseBMI, body mass indexCHOP, The Children’s Hospital of PhiladelphiaCMR, cardiometabolic riskCTRC, Clinical and Translational Research CenterCV, coefficient of variationDRIs, dietary reference intakesDXA, dual X-ray absorptiometryELISA, enzyme-linked immunosorbent assayFA, fat areaFMI, fat mass indexHDL-C, high-density lipoprotein cholesterolHOMA-IR, homeostatic model assessment of insulin resistancehs-CRP, high-sensitivity C-reactive proteinIOM, Institute of MedicineIU, international unitsLDL-C, low-density lipoprotein cholesterolNMR, nuclear magnetic resonancePTH, parathyroid hormoneSD, standard deviationTC, total cholesterolTG, triglyceridesVDBP, vitamin D binding protein

Identifiers

PMID29892560
PMCPMC5992315
OpenAlexW2789263399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.